TY - CHAP M1 - Book, Section TI - Colistin and Polymyxin B A1 - VOIGT, LISA M. A1 - ZAMMIT, KIMBERLY T. A2 - Cohen, Henry PY - 2015 T2 - Casebook in Clinical Pharmacokinetics and Drug Dosing AB - Antimicrobial resistance has become a worldwide health care crisis with many pathogens showing limited or no susceptibility to currently available antimicrobial treatments. Gram-negative infections are of even more concern because of the lack of currently effective treatments, as well as the lack of new antibiotics in development to treat these potentially lethal pathogens. It is currently estimated that no new antibiotics with activity against multiresistant gram-negative bacteria will be released within the next five years, emphasizing the need for last-line options, such as colistin, in cases where pathogens are resistant to all other antibiotics. in the last two decades, the paucity of novel antibiotics with which to treat drug-resistant infections, especially those caused by gram-negative pathogens, has led to their reconsideration as a therapeutic option.1 SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - accesspharmacy.mhmedical.com/content.aspx?aid=1112257499 ER -